TrialRespiratory research2017

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.

Krishna K Pudi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.